Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 9/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1606814 | 0.82 | CYP11B2 (0.71) | CYP11B2CYP11B1MAOACYP19A1NTRK1 | |
| SCHEMBL3678336 | 0.77 | CYP11B2 (0.64) | CYP11B2CYP11B1MAOACYP19A1NTRK1 | |
| SCHEMBL3680547 | 0.74 | CYP11B2 (0.62) | CYP11B2CYP11B1MAOACYP19A1NTRK1 | |
| SCHEMBL1605831 | 0.72 | CYP11B2 (0.65) | CYP11B2CYP11B1MAOACYP19A1NTRK1 | |
| SCHEMBL1606215 | 0.71 | CYP11B2 (0.69) | CYP11B2CYP11B1MAOACYP19A1 | |
| SCHEMBL3685371 | 0.71 | CYP11B2 (0.55) | CYP11B2CYP11B1MAOACYP19A1NTRK1 | |
| SCHEMBL1605285 | 0.71 | CYP11B2 (0.72) | CYP11B2CYP11B1MAOACYP19A1NTRK1 | |
| SCHEMBL3683231 | 0.71 | CYP11B2 (0.53) | CYP11B2CYP11B1MAOACYP19A1KDM1A | |
| SCHEMBL1606125 | 0.69 | CYP11B2 (0.67) | CYP11B2CYP11B1MAOACYP19A1NTRK1 | |
| SCHEMBL1606378 | 0.69 | CYP11B2 (0.70) | CYP11B2CYP11B1MAOACYP19A1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307371-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | disclosed |
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20140288126-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-8791141-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261698-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | CYP11B2 13/4885CYP11B1 14/4885MAOA 193/4885 |
| US-20150210672-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | CYP11B2 12/4885CYP11B1 15/4885MAOA 198/4885 |
| US-20140288126-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | CYP11B2 12/4885CYP11B1 15/4885MAOA 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.